Maximizing the Outcomes of Breast Cancer Prevention
Cancer mortality in the United States has declined by about 1.5% per year since 1999. Patients with most of the common solid tumors have experienced decreased mortality risk over this period, including those with breast cancer, in whom mortality fell by 1.8% per year between 1998 and 2016. Although there is much to celebrate in these statistics, there is still a long way to go. Breast cancer remains the second leading cause of cancer death among US women, with an estimated 42 000 deaths in 2018. At this rate, it would take 80 years for breast cancer mortality to fall to less than 10 000 women per year.
Authors: Liang C, Li N, Cai Z, Liang R, Zheng X, Deng L, Feng L, Guo R, Wei B Abstract At present, cancer is the first cause of death for humans, but early detection and treatment can help improve prognoses and reduce mortality. However, further development of carrier-assistant drug delivery systems (DDSs) is retarded by the aspects such as the low drug-carrying capacity, carrier-induced toxicity and immunogenicity, complex synthesis manipulation. The development of nanoscale drug delivery systems (NDDS) have been rapidly developed to address these issues. In this article, we used PLGA-PEG with good biocompatibilit...
Garlic and ginger pills can delay the healing of skin wounds when breast cancer spreads, expert says.
Findings seen among postmenopausal breast cancer patients regardless of activity level prediagnosis
Publication date: Available online 13 November 2019Source: American Journal of Preventive MedicineAuthor(s): Ethan O. Cohen, Olena O. Weaver, Hilda H. Tso, Karen E. Gerlach, Jessica W.T. Leung
Conclusions: Intra- and inter-provincial differences in the use of chemotherapy and acute care were observed. Understanding variations in care can help to identify gaps and opportunities for improvement and shared learnings. PMID: 31708656 [PubMed - in process]
Conclusions: Use of the 21-gene rs assay could be a cost-effective strategy for Ontario patients with estrogen receptor-positive, her2-negative early bca and 1-3 positive lns. PMID: 31708649 [PubMed - in process]
Might detection of mutations in CHEK2 be useful as a prognostic factor for patient response to treatment or potential for metastasis in breast cancer?Laboratory Medicine
In a new study, patients with HR+/HER2- early stage breast cancer completed 2 years of adjuvant palbociclib with a similar toxicity profile as that observed in the metastatic setting.Annals of Oncology